Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...

Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...

Sanofi SNY announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis ...

An update from Quantum Biopharma ( ($TSE:QNTM) ) is now available. On December 23, 2025, Quantum BioPharma announced it has completed oral dosing ...

Investing.com -- Sanofi SA (EPA:SASY) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application of tolebrutinib, which was ...

Study Links Mediterranean Diet to Lower Multiple Sclerosis Risk Levels Eating your way to brain health might be simpler than ...

Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 TrialTORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: ...

Sanofi agreed to buy Dynavax Technologies Corp for about US$2.2 billion, as the French drugmaker tries to expand a vaccines ...

Trump on Friday announced what the White House described as the largest set of developments to date under his administration’s push to bring prescription drug prices in the United States in line with ...

The year will soon come to a close, but it feels like just yesterday when these stories were hitting the headlines.

Shares of Dynavax Technologies surged after Sanofi said it was buying the vaccine specialist for $2.2 billion in cash. The stock jumped 39% to $15.44 midday Wednesday after hitting a 52-week high of ...